Istesso develops first-in-class oral regenerative medicines focused on restoring the body's natural capacity to repair tissue. The company's approach centers on mitochondrial Complex I modulators (MCMs), a new class of small molecule drugs targeting tissue regeneration across multiple disease settings. Their lead clinical program, leramistat, is advancing through trials for chronic age-related diseases.
Funding
$13.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for autoimmune disorders and fibrosis primarily focus on modifying symptoms and slowing disease progression, but they often fail to reverse existing tissue damage or restore normal physiological function. This leaves a significant unmet need for therapies that can actively rebuild damaged tissue and resolve the underlying disease.
Solution
Istesso is developing programmed disease-resolving drugs designed to rebuild damaged tissue and restore normal physiological function in patients with autoimmune and fibrotic disorders. Their approach aims to go beyond conventional disease modification by actively reversing disease and enabling patients to regain lost function. Istesso's drugs carefully control inflammation while preserving repair-inducing drivers, unlocking the body's endogenous regenerative capacity and ensuring that tissue remodeling proceeds without fibrosis. The company's lead asset, Leramistat, is currently in development for rheumatoid arthritis and idiopathic pulmonary fibrosis (IPF). Istesso is also developing MBS2687 for autoimmune, neuroprotection/fibrosis, and IST004 for neuroprotection/autoimmunity.
Target Audience
The primary target audience includes patients suffering from autoimmune disorders and fibrosis, as well as healthcare providers specializing in these conditions.
Features
- Leramistat: A drug in development for rheumatoid arthritis and idiopathic pulmonary fibrosis (IPF)
- MBS2687: A drug in development for autoimmune, neuroprotection/fibrosis
- IST004: A drug in development for neuroprotection/autoimmunity
- Aims to control inflammation while preserving repair-inducing drivers
- Designed to unlock the body's endogenous regenerative capacity
- Seeks to ensure tissue remodeling proceeds normally, without fibrosis